StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Lidocaine Hydrochloride

HCID 6314
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
6108-05-0
Standard-SMILES
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl
InChIKey
IYBQHJMYDGVZRY-UHFFFAOYSA-N
Summenformel
C14H23ClN2O
Durchschnittliche Molmasse
270,8 g/mol
Monoisotopische Masse
270,14989104

Überblick

Lidocaine Hydrochloride is the hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class anesthetics. Lidocaine interacts with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue, especially on the Purkinje network, during phase 0 of the action potential, thereby decreasing depolarization, automaticity and excitability.

Namen und Bezeichner

Bevorzugter Name
Lidocaine Hydrochloride
IUPAC
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
Englischer Name
Lidocaine hydrochloride
Summenformel
C14H25ClN2O2
Molmasse
288.82

Namen und Synonyme

Lidocaine hydrochloride73-78-9LIDOCAINE HCLLidothesinLignocaine hydrochlorideLaryng-O-jetAnestaconLidocatonGlydoXylocaine ViscousLIDOCAINE VISCOUSLTA II KIT
Weitere Namen anzeigen
LINOCAINE HYDROCHLORIDELINOCAINE HCLLinocaine hydrochlorLinocaine hydrochloride monohydrateLignocaine hydrochloride monohydrateLinocaine hydrochloride(lidocaine HCL)2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride hydrate2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrate hydrochlorideACETAMIDE,2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)-MONOHYDROCHLORIDE, MONOHYDRATEdolicaine
PEDIATRIC LTA KITLARYNG-O-JET KITLidocaine hydrochloride anhydrousLIDOPENZingoEC2CNF7XFPXYLOCAINE PRESERVATIVE FREELARYNGOTRACHEAL ANESTHESIA KIT

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
32,3 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
5
Schwere Atome
18
Formalladung
0
Komplexität
228

Experimentelle und physikochemische Eigenschaften

Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antiarrhythmics; Local Anesthetics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section155.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
75 · 75-79℃
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: soluble
Aggregatzustand
solid
Farbe
white
Wasserlöslichkeit
Soluble in water (50 mg/ml), chloroform, ethanol, and benzene. Insoluble in diethyl ether.
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C14H22N2O.ClH.H2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4;;/h7-9H,5-6,10H2,1-4H3,(H,15,17);1H;1H2
InChIKey

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H301 (82.5%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P301+P317, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 183 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H301 (46.3%): Toxic if swallowed [Danger Acute toxicity, oral]

Gefahrenhinweise

Regulatory InformationLidocaine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride: Environment tier I assessment
Hazard Classes and Categories · 2 Einträge

Acute Tox. 3 (46.3%)

Acute Tox. 3 (82.5%)

Toxikologische Informationen

Treatment · 1 Eintrag

The first step in the management of systemic toxic reactions consists of immediate attention to the establishment and maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. If convulsions occur, the objective of the treatment is to maintain ventilation and oxygenation and support the circulation. Oxygen must be given and ventilation assisted if necessary (mask and bag or tracheal intubation). Should convulsions not stop spontaneously after 15-20 seconds, an anticonvulsant should be given i.v. to facilitate adequate ventilation and oxygenation. Thiopental sodium 1-3 mg/kg i.v. is the first choice. Alternatively diazepam 0.1 mg/kg bw i.v. may be used, although its action will be slow. Prolonged convulsions may jeopardise the patient's ventilation and oxygenation. If so, injection of a muscle relaxant (e.g. succinylcholine 1 mg/kg bw) will facilitate ventilation, and oxygenation can be controlled. Early endotracheal intubation must be considered in such situations. If cardiovascular depression is evident (hypotension, bradycardia), ephedrine 5-10 mg i.v. should be given and may be repeated, if necessary, after 2-3 minutes. Should circulatory arrest occur, immediate cardiopulmonary resuscitation should be instituted. Continual oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance. (L1712)

Chemie und Industrie

Pharmakologische Informationen

Metabolism/MetabolitesPrimarily hepatic. Route of Elimination: Lidocaine and its metabolites are excreted by the kidneys. Half Life: 109 minutes
FDA Pharmacological Classification · 6 Einträge

0.5% LIDOCAINE HCL

Local Anesthesia [PE]; Antiarrhythmic [EPC]; Amide Local Anesthetic [EPC]; Amides [CS]

1% LIDOCAINE HCI

Local Anesthesia [PE]; Amide Local Anesthetic [EPC]; Antiarrhythmic [EPC]; Amides [CS]

2% LIDOCAINE HCI

Local Anesthesia [PE]; Antiarrhythmic [EPC]; Amide Local Anesthetic [EPC]; Amides [CS]

MeSH Pharmacological Classification · 3 Einträge

Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Verwendung und Herstellung

Uses · 1 Eintrag

For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 240241
HRID 240241als Edukt
Reaktionsgleichung von HRID 240242
HRID 240242als Edukt
Reaktionsgleichung von HRID 240243
HRID 240243als Edukt
Reaktionsgleichung von HRID 342317
HRID 342317als Produktals Edukt
Reaktionsgleichung von HRID 362738
HRID 362738als Produktals Edukt
Reaktionsgleichung von HRID 1517223
HRID 1517223als Edukt
Reaktionsgleichung von HRID 1585955
HRID 1585955als Produktals Edukt
Reaktionsgleichung von HRID 2191206
HRID 2191206als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
6108-05-0、73-78-9
PubChem CID
6314
DTXSID
DTXSID4058782
ChEMBL
CHEMBL1200409、CHEMBL541521
UNII
EC2CNF7XFP
EC Number
200-803-8、612-079-4
YECIFGHRMFEPJK-UHFFFAOYSA-N
SMILES
C1(C(C)=CC=CC=1C)NC(=O)CN(CC)CC.O.Cl
LogP
2.359 · 2.359 (est)
CAS Datenbank
6108 · 6108-05-0(CAS DataBase Reference)
Health Effects · 1 Eintrag

Systemic exposure to excessive quantities of lidocaine mainly result in central nervous system (CNS) and cardiovascular effects. CNS effects may include CNS excitation(nervousness, tingling around the mouth) followed by depression. [Wikipedia]

Exposure Routes · 1 Eintrag

Intravenous, Topical, Oral, Buccal, Dental, Intramuscular, or Urethral injection , Infiltration. Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.

Toxicity Summary · 1 Eintrag

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anaesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their birth in the first place.

Signs and SymptomsSymptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 459 (346-773) mg/kg (oral, non-fasted female rats) LD50: 214 (159-324) mg/kg (oral, fasted female rats)

Sicherheitsdaten

wgk
3
tsca
Yes
ridadr
UN 2811 6.1/PG 3
hs_code
2924296000
RTECS-Nr.
AN7700000
risk_code
22
hazard_code
Xn
safety_code
36
hazard_class
6.1
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 Oral
Household ProductsInformation on 1 consumer products that contain Lidocaine hydrochloride in the following categories is provided:
General Manufacturing InformationAcetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride (1:1): ACTIVE
Anwendungen · 1 Eintrag

VerwendenLinocaine hydrochloride is a fast voltage-gated sodium channel blocker that used in Local anesthesia and heart rhythm disorders. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine.

Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: Linocaine hydrochloride is the monohydrate form of lidocaine hydrochloride. It is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of Procaine but its duration of action is shorter than that of bupivacaine or prilocaine.